×
About 3,764 results

ALLMedicine™ Mycoplasma Pneumoniae Center

Research & Reviews  1,629 results

Risk factors for delayed radiographic resolution in children with refractory Mycoplasma...
https://doi.org/10.1177/03000605211015579
The Journal of International Medical Research; Yan Q, Niu W et. al.

May 26th, 2021 - To determine the risk factors for delayed radiographic resolution in children with refractory Mycoplasma pneumoniae pneumonia (RMPP) and explore the most suitable time for interventional bronchoscopy. This retrospective study involved 142 children...

Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA.
https://doi.org/10.3201/eid2706.203206
Emerging Infectious Diseases; Lanata MM, Wang H et. al.

May 20th, 2021 - Emergence of macrolide-resistant Mycoplasma pneumoniae (MRMp) challenges empiric macrolide therapy. Our goal was to determine MRMp rates and define characteristics of children infected with macrolide-sensitive M. pneumoniae (MSMp) versus MRMp in O...

Prediction model for prolonged fever in patients with Mycoplasma pneumoniae pneumonia: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130327
BMC Pulmonary Medicine; Jang MS, Kim BG et. al.

May 19th, 2021 - To identify patients with Mycoplasma pneumoniae pneumonia (MPP) with a risk of prolonged fever while on macrolides. A retrospective study was performed with 716 children admitted for MPP. Refractory MPP (RMPP-3) was defined as fever persisting for...

Mycoplasma pneumoniae P1 genotype indicates severity of lower respiratory tract infecti...
https://doi.org/10.1128/JCM.00220-21
Journal of Clinical Microbiology; Rodman Berlot J, Krivec U et. al.

May 13th, 2021 - Background. Mycoplasma pneumoniae (M. pneumoniae) strains can be classified into two major genetic groups, P1 type 1 (P1-1) and P1 type 2 (P1-2). It remains unknown if clinical manifestations of lower respiratory tract infections (LRTI) in childre...

Predicting Mycoplasma pneumoniae and Chlamydophila pneumoniae in community-acquired pne...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116829
Internal and Emergency Medicine; Ishimaru N, Suzuki S et. al.

May 13th, 2021 - Community-acquired pneumonia (CAP) is a common illness that can lead to mortality. β-lactams are ineffective against atypical pathogen including Mycoplasma pneumoniae. We used molecular examinations to develop a decision tree to predict atypical p...

see more →

Drugs  223 results see all →

Clinicaltrials.gov  1,879 results

Risk factors for delayed radiographic resolution in children with refractory Mycoplasma...
https://doi.org/10.1177/03000605211015579
The Journal of International Medical Research; Yan Q, Niu W et. al.

May 26th, 2021 - To determine the risk factors for delayed radiographic resolution in children with refractory Mycoplasma pneumoniae pneumonia (RMPP) and explore the most suitable time for interventional bronchoscopy. This retrospective study involved 142 children...

Minocycline hydrochloride - minocycline hydrochloride capsule-A-S Medication Solutions
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7d0226e-5ac5-4fb1-9849-9d6663a2e8ad

May 24th, 2021 - Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpo...

Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA.
https://doi.org/10.3201/eid2706.203206
Emerging Infectious Diseases; Lanata MM, Wang H et. al.

May 20th, 2021 - Emergence of macrolide-resistant Mycoplasma pneumoniae (MRMp) challenges empiric macrolide therapy. Our goal was to determine MRMp rates and define characteristics of children infected with macrolide-sensitive M. pneumoniae (MSMp) versus MRMp in O...

Prediction model for prolonged fever in patients with Mycoplasma pneumoniae pneumonia: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130327
BMC Pulmonary Medicine; Jang MS, Kim BG et. al.

May 19th, 2021 - To identify patients with Mycoplasma pneumoniae pneumonia (MPP) with a risk of prolonged fever while on macrolides. A retrospective study was performed with 716 children admitted for MPP. Refractory MPP (RMPP-3) was defined as fever persisting for...

Mycoplasma pneumoniae P1 genotype indicates severity of lower respiratory tract infecti...
https://doi.org/10.1128/JCM.00220-21
Journal of Clinical Microbiology; Rodman Berlot J, Krivec U et. al.

May 13th, 2021 - Background. Mycoplasma pneumoniae (M. pneumoniae) strains can be classified into two major genetic groups, P1 type 1 (P1-1) and P1 type 2 (P1-2). It remains unknown if clinical manifestations of lower respiratory tract infections (LRTI) in childre...

see more →

News  33 results

Fast Five Quiz: Mycoplasma genitalium Presentation and Diagnosis
https://reference.medscape.com/viewarticle/926618_6

Apr 8th, 2020 - According to BASHH guidelines, testing for M genitalium is recommended for all women with signs and symptoms of cervicitis or PID. CDC guidelines recommend testing in women with recurrent/persistent PID. M genitalium testing is also recommended fo...

Pneumonia with tender, dry, crusted lips
https://www.mdedge.com/node/208253/path_term/51947
Safiyyah Bhatti, MD, Lawrence F. Eichenfield, MD

Sep 17th, 2019 - Mycoplasma pneumoniae infection commonly manifests as an upper or lower respiratory tract infection with associated fever, dyspnea, cough, and coryza. However, patients can present with extrapulmonary complications with dermatologic findings inclu.

FDA OKs First-in-Class Antibiotic Lefamulin (Xenleta) for CABP
https://www.staging.medscape.com/viewarticle/917020

Aug 18th, 2019 - The US Food and Drug Administration (FDA) has approved lefamulin (Xenleta, Nabriva Theraputics), a new oral and intravenous (IV) antibiotic for the treatment of adults with community-acquired bacterial pneumonia (CABP). Lefamulin is a first-in-cla...

FDA OKs First-in-Class Antibiotic Lefamulin (Xenleta) for CABP
https://www.medscape.com/viewarticle/917020

Aug 18th, 2019 - The US Food and Drug Administration (FDA) has approved lefamulin (Xenleta, Nabriva Theraputics), a new oral and intravenous (IV) antibiotic for the treatment of adults with community-acquired bacterial pneumonia (CABP). Lefamulin is a first-in-cla...

Make the Diagnosis - October 2016
https://www.mdedge.com/dermatology/article/116212/make-diagnosis-october-2016
Dr. Donna Bilu Martin

Oct 1st, 2016 - Erythema multiforme Erythema multiforme (EM) is a hypersensitivity reaction. Cutaneous lesions generally occur symmetrically on the extensor surfaces of the acral extremities and spread centripetally.

see more →